IP Library Granted Patent US 7,754,464
Granted Patent B2
US 7,754,464 · App. 11/113,751 · Granted Jul 13, 2010

Cellular permissivity factor for viruses and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,464
App. No.
11/113,751
Granted
Jul 13, 2010
Kind
B2
Abstract

The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.

Claims (19)

1. A method of facilitating production of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) from a culture of vertebrate cells, comprising the steps of:

(a) providing a recombinant vertebrate cell transfected with an exogenous polynucleotide that encodes a mammalian CD163 polypeptide having a transmembrane domain and at least 70% sequence identity to SEQ ID NO:14, so that expression of CD163 polypeptide in said cell is increased;

(b) contacting a culture of said cell with PRRSV virus under conditions which permit infection of the cells and growth of the virus; and

(c) recovering virus from said culture.

2. The method of claim 1 , wherein the cell was previously permissive PRRSV permissive and is rendered more PRRSV permissive.

3. The method of claim 1 , wherein the cell did not previously express a CD163 polypeptide and is induced to express CD163.

4. The method of claim 1 , wherein the cell is selected from the group consisting of baby hamster kidney cells (BHK21), porcine kidney cells, feline kidney cells, avian cells, and swine testicular cells.

5. The method of claim 1 , wherein the PRRSV is of the European genotype.

6. The method of claim 1 , wherein the PRRSV is of the North American genotype.

7. The method of claim 1 , wherein the polynucleotide encodes a polypeptide having a transmembrane domain and at least 90% sequence identity to SEQ ID NO:14.

8. The method of claim 1 , wherein the polynucleotide encodes a polypeptide having a transmembrane domain and at least 90% sequence identity to SEQ ID NO:19.

9. The method of claim 1 , wherein the polynucleotide encodes a polypeptide having a transmembrane domain and at least 97% sequence identity to SEQ ID NO:24.

10. The method of claim 1 , wherein the polynucleotide encodes a polypeptide having a transmembrane domain and at least 90% sequence identity to SEQ ID NO:32.

11. The method of claim 1 , wherein the polynucleotide encodes a polypeptide having a transmembrane domain and at least 90% sequence identity to SEQ ID NO:46.

12. The method of claim 1 , further comprising the step of producing a vaccine from the recovered virus.

13. The method of claim 12 , wherein the vaccine comprises inactivated virus.

14. The method of claim 12 , wherein the vaccine comprises live attenuated virus.

15. The method of claim 1 , wherein transfection with an exogenous polynucleotide that encodes a mammalian CD163 polypeptide is accomplished by electroporation.

16. The method of claim 1 , wherein said recombinant vertebrate cell is transfected with an exogenous polynucleotide that encodes a fusion protein which includes mammalian CD163 polypeptide.

Assignments (2)
ADDRESS CHANGE OF ASSIGNEE Recorded Jun 5, 2017
From: ZOETIS SERVICES LLC
To: ZOETIS SERVICES LLC
Reel/Frame 042683/0199 →
MERGER Recorded May 13, 2015
From: ZOETIS P&U LLC
To: ZOETIS SERVICES LLC
Reel/Frame 035623/0700 →